Nkarta (NKTX) Participates in Evercore 8th Annual Healthcare Conference to Showcase NK Cell Therapy Progress

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Dec 02 2025

0mins

NKTX+5.21%

Should l Buy NKTX?

Source: Globenewswire

Conference Participation: Nkarta will participate in the Evercore 8th Annual Healthcare Conference on December 4 in Miami, showcasing its progress in NK cell therapies for autoimmune diseases, which is expected to attract investor and industry attention.
Live Webcast: The event is scheduled for 10:50 a.m. ET and will be simultaneously webcast on Nkarta's investor section of its website, allowing global investors to access real-time information.
Replay Availability: Following the conference, a replay will be archived on Nkarta's website for approximately 90 days, ensuring that investors who cannot attend live can still access relevant information, thereby enhancing the company's transparency.
Company Background: Nkarta focuses on developing allogeneic, off-the-shelf NK cell therapies, combining cell expansion and cryopreservation platforms to provide deep therapeutic activity intended for broad outpatient access, demonstrating its innovative potential in the biopharmaceutical sector.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy NKTX?" and start using high-conviction signals backed by rigorous historical data.

NKTX

$2.02+Infinity%1D

Analyst Views on NKTX

Wall Street analysts forecast NKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NKTX is 12.33 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Analyst Rating

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 1.920

Low

10.00

Averages

12.33

High

16.00

Current: 1.920

Low

10.00

Averages

12.33

High

16.00

Stifel

Buy

downgrade

$12 -> $11

2025-11-11

Reason

Stifel

Price Target

$12 -> $11

AI Analysis

2025-11-11

downgrade

Buy

Reason

Stifel lowered the firm's price target on Nkarta to $11 from $12 and keeps a Buy rating on the shares. The firm believes management's decision to forego a preliminary year-end 2025 data disclosure and instead guide to the presentation of a more-fulsome data set at a FY26 medical conference should remove a near-term overhang given the former disclosure format was perceived to be mostly inconclusive, the analyst tells investors following the Q3 update.

Stifel

Stephen Willey

Buy

downgrade

$14 -> $12

2025-08-14

Reason

Stifel

Stephen Willey

Price Target

$14 -> $12

2025-08-14

downgrade

Buy

Reason

Stifel analyst Stephen Willey lowered the firm's price target on Nkarta to $12 from $14 and keeps a Buy rating on the shares. The recent earnings announcement and corporate update did not provide "any incremental surprises" as management is still guiding to the disclosure of preliminary data from the Ntrust-1/2 trials evaluating NKX019 in autoimmune disease before year-end, the analyst tells investors. The firm's reduced price target mostly reflects revised longer-term financing assumptions and valuation, the analyst noted.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NKTX

Unlock Now

About NKTX

Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ImmunityBio Shares Triple in Three Weeks, Short-Sellers Face $500 Million Loss

Jan 21 2026Yahoo Finance

Price Surge: ImmunityBio's stock price has tripled over three weeks, closing at $6.92 on Wednesday with a 6.79% increase, indicating strong market interest in its immunotherapy developments, potentially attracting more investors.
Volume Spike: Trading volume reached 93.5 million shares on Wednesday, about 357% above the three-month average of 20.5 million shares, signaling a significant rise in investor attention that could lead to further price volatility.
Short-Seller Losses: With 35% of the public float held short, short-sellers now face nearly $500 million in paper losses, reflecting optimistic market sentiment towards ImmunityBio's future developments, which may prompt short-covering to mitigate losses.
Market Reaction: Although there was no specific news driving the price increase, the actions of short-sellers covering their positions combined with recent positive developments have contributed to the stock's rise, showcasing ongoing interest in the biotechnology sector.